|
1
|
Heymann D and Rédini F: Targeted therapies
for bone sarcomas. Bonekey Rep. 2:3782013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hoch M, Ali S, Agrawal S, Wang C and
Khurana JS: Extraskeletal osteosarcoma: a case report and review of
the literature. J Radiol Case Rep. 7:15–23. 2013.PubMed/NCBI
|
|
3
|
Vikram S, Salih S, Krishnan A, et al:
Radiation-induced extra-osseous osteosarcoma - A case report and
review of literature. Indian J Surg Oncol. 4:374–377. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Puri A, Pruthi M and Gulia A: Outcomes
after limb sparing resection in primary malignant pelvic tumors.
Eur J Surg Oncol. 40:27–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tao LJ, Zhou XD, Shen CC, et al:
Tetrandrine induces apoptosis and triggers a caspase cascade in
U2-OS and MG-63 cells through the intrinsic and extrinsic pathways.
Mol Med Rep. 9:345–349. 2014.PubMed/NCBI
|
|
6
|
Zhao Z, Tao L, Shen C, Liu B, Yang Z and
Tao H: Silencing of Barkor/ATG14 sensitizes osteosarcoma cells to
cisplatin-induced apoptosis. Int J Mol Med. 33:271–276.
2014.PubMed/NCBI
|
|
7
|
Uno K, Tsukuda M, Kushida K, et al:
Clinical experience with In-111 labeled LAK cells and TILS for
tumor localization. Prog Clin Biol Res. 355:239–245.
1990.PubMed/NCBI
|
|
8
|
Luksch R, Perotti D, Cefalo G, et al:
Immunomodulation in a treatment program including pre- and
post-operative interleukin-2 and chemotherapy for childhood
osteosarcoma. Tumori. 89:263–268. 2003.PubMed/NCBI
|
|
9
|
Herrero-Martín D, Osuna D, Ordóñez JL, et
al: Stable interference of EWS-FLI1 in an Ewing sarcoma cell line
impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target.
Br J Cancer. 101:80–90. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Park JH, Yoon DS, Choi HJ, Hahm DH and Oh
SM: Phosphorylation of IκBα at serine 32 by T-lymphokine-activated
killer cell-originated protein kinase is essential for
chemoresistance against doxorubicin in cervical cancer cells. J
Biol Chem. 288:3585–3593. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jennings VA, Ilett EJ, Scott KJ, et al:
Lymphokine-activated killer and dendritic cell carriage enhances
oncolytic reovirus therapy for ovarian cancer by overcoming
antibody neutralization in ascites. Int J Cancer. 134:1091–1101.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tjota A, Zhang YQ, Piedmonte MR and Lee
CL: Adoptive immunotherapy using lymphokine-activated killer cells
and recombinant interleukin-2 in preventing and treating
spontaneous pulmonary metastases of syngeneic Dunning rat prostate
tumor. J Urol. 146:177–183. 1991.PubMed/NCBI
|
|
13
|
Gillette J and Nielsen-Preiss S: Cancer
stem cells: seeds of growth in osteosarcoma. Cancer Biol Ther.
8:553–554. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tomuleasa C, Soritau O, Brie I, et al:
Mesenchymal stem cell irradiation in culture engages differential
effect of hyper-fractionated radiotherapy for head and neck
cancers. J BUON. 15:348–356. 2010.PubMed/NCBI
|
|
15
|
Siclari VA and Qin L: Targeting the
osteosarcoma cancer stem cell. J Orthop Surg Res. 5:782010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Longhi A, Errani C, De Paolis M, Mercuri M
and Bacci G: Primary bone osteosarcoma in the pediatric age: state
of the art. Cancer Treat Rev. 32:423–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fujii H, Honoki K, Tsujiuchi T, Kido A,
Yoshitani K and Takakura Y: Sphere-forming stem-like cell
populations with drug resistance in human sarcoma cell lines. Int J
Oncol. 34:1381–1386. 2009.PubMed/NCBI
|
|
18
|
Ta HT, Dass CR, Choong PF and Dunstan DE:
Osteosarcoma treatment: state of the art. Cancer Metastasis Rev.
28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang SY and Shi Y: Reaction of low dose
ionizing radiation on amplification in vitro and antitumor effect
of TIL cells. Chinese Journal of Cancer Prevention and Treatment.
16:1552–1553. 2009.
|
|
20
|
Fu Q, Zhang LS, Zhu SP and Liu XH: Effects
of low-dose radiation on LAK cells to kill tumor target cells.
Chinese Journal of Radiological Medicine and Protection.
15:3211995.
|
|
21
|
Wang YC, Shi EX and Ding XL: Killing
effect on lung cancer cell line A549 by lymphokine-activated killer
cells activated by dendritic cells. Northern China National Defense
Medicine. 21:11–12. 2009.
|
|
22
|
Yanagawa H, Sone S, Fukuta K, Nishioka Y
and Ogura T: Local adoptive immunotherapy using
lymphokine-activated killer cells and interleukin-2 against
malignant pleural mesothelioma: Report of two cases. Jpn J Clin
Oncol. 21:377–383. 1991.PubMed/NCBI
|
|
23
|
Mou QJ, Wang J, Cui WF and Wang ZJ:
Proliferation and cytotoxic activity comparison of three sources of
CIK cells. Shandong Medicine. 50:7–9. 2010.
|
|
24
|
Barba D, Saris SC, Holder C, Rosenberg SA
and Oldfield EH: Intratumoral LAK cell and interleukin-2 therapy of
human gliomas. J Neurosurg. 70:175–182. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Balasa B, Yun R, Belmar NA, et al:
Elotuzumab enhances natural killer cell activation and myeloma cell
killing through interleukin-2 and TNF-α pathways. Cancer Immunol
Immunother. 64:61–73. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jin P, Wang E, Provenzano M, et al:
Molecular signatures induced by interleukin-2 on peripheral blood
mononuclear cells and T cell subsets. J Transl Med. 4:262006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jinxia Ai and Huanbo Cui: The effect of
SBHL on the tumor growth and immune functions in S180-bearing mice.
Zhong Guo Mian Yi Xue Za Zhi. 26:26–29. 2010.(In Chinese).
|
|
28
|
Parhar RS, Ernst P, Sheth KV and
al-Sedairy ST: Anti-tumor cytotoxic potential and effect on human
bone marrow GM-CFU of human LAK cells generated in response to
various cytokines. Eur Cytokine Netw. 3:299–306. 1992.PubMed/NCBI
|
